Growing Apart: Culture-Based Sterility Test Alternatives

November 19, 2026 - 03:05
 0  0
Growing Apart: Culture-Based Sterility Test Alternatives

In the biopharma industry, culture-based microbial sterility testing methods are not fast enough for personalized cell therapy production, say the developers of a new parallel analysis pathway.

Bacterial contamination is always a risk in biopharmaceutical production. The complex, multi-step nature of processes, the nutrient-rich, aqueous environments in which cells are cultured—and even the raw materials themselves—provide potential entry points for microorganisms.

As a result, regulators require that biopharmaceuticals undergo extensive analysis using standardized procedures. Typically, product samples are cultured to allow any bacterial or fungal contaminants to grow, enabling full identification.

For high-volume products made in multiple, sequential batches—protein therapeutics, monoclonal antibodies—these long testing processes can be incorporated into the manufacturing lifecycle without interrupting market supply.

For firms making single-batch, patient-specific therapies, any steps that delay release, including long sterility testing processes, are hard to accommodate, according to Athena Stathoulis, a researcher at the University of Melbourne in Australia.

“The gold-standard sterility test for cell therapies, USP <71>, takes 14 days to give a result. Fresh CAR T products often have to be infused within 24–72 hours, so the product reaches the patient long before its sterility is confirmed,” she tells GEN.

In practice, the need to deliver CAR T cell therapies to patients as soon as possible means they are often released early, under exceptional protocols based on interim culture results at around 48 hours, Stathoulis explains.

“This approach shortens the detection window and risks missing slow-growing organisms, with full sterility confirmation only arriving after the patient has been infused. This matters because vein-to-vein time is linked to outcomes,” she adds.

Stathoulis, who examined cell therapy sector practices in a recent study, also points out that, unlike steps like leukapheresis, transduction, and expansion that can be optimized, the timelines for sterility testing are fixed by regulatory mandate.

“Sterility testing is the one manufacturing bottleneck that process optimization can’t fix, because the incubation period is set by regulation, not biology. That makes it the rate-limiting step for point-of-care and decentralized CAR T manufacturing.”

Solutions

Cell therapy firms do have potential alternative testing options, Stathoulis says, with the most promising being assays that do not rely on bacterial growth.

“The main alternatives are ATP bioluminescence, solid-phase cytometry, and molecular assays targeting conserved bacterial and fungal ribosomal RNA genes (16S/18S rRNA).

“In our view, the molecular assays are the most compelling. They are not growth-dependent, removing the need for incubation altogether and providing results within hours,” Stathoulis explains.

Another potential alternative, which Stathoulis and colleagues propose in the study, would be to run a combination of sterility testing methods in parallel.

“Our review proposes a three-phase pathway that moves toward this: comprising analytical qualification; then parallel testing alongside compendial methods; and then conditional release,” she says.

Measures set out in the proposed pathway include testing against a facility-specific panel of at least 20 organisms, including skin flora such as Cutibacterium acnes, Gram-negative bacteria, fungi, and slow-growing organisms.

The pathway also calls for the use of viability dyes and enrichment steps to reduce the risk of false positives and false negatives, as well as compendial testing after infusion as a safety net, with a predefined plan for when the rapid and compendial results disagree.

Adoption

The degree to which cell therapy firms can use alternative methods depends on regulators, according to Stathoulis, who says, “The barriers to adopting rapid sterility methods are regulatory rather than analytical, and regulation can be reformed. The main obstacles are regulatory fragmentation between the FDA, EMA, and TGA, and a lack of real-world validation data in CAR T products.”

The post Growing Apart: Culture-Based Sterility Test Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News.

Apa Reaksi Anda?

Suka Suka 0
Kurang Suka Kurang Suka 0
Setuju Setuju 0
Tidak Setuju Tidak Setuju 0
Bagus  Bagus 0
Berguna Berguna 0
Hebat Hebat 0
Edusehat Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. || An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.